262 related articles for article (PubMed ID: 30099987)
1. Regulation of the Activity in the p53 Family Depends on the Organization of the Transactivation Domain.
Krauskopf K; Gebel J; Kazemi S; Tuppi M; Löhr F; Schäfer B; Koch J; Güntert P; Dötsch V; Kehrloesser S
Structure; 2018 Aug; 26(8):1091-1100.e4. PubMed ID: 30099987
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic aggregation propensity of the p63 and p73 TI domains correlates with p53R175H interaction and suggests further significance of aggregation events in the p53 family.
Kehrloesser S; Osterburg C; Tuppi M; Schäfer B; Vousden KH; Dötsch V
Cell Death Differ; 2016 Dec; 23(12):1952-1960. PubMed ID: 27447112
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis of the interactions between the p73 N terminus and p300: effects on transactivation and modulation by phosphorylation.
Burge S; Teufel DP; Townsley FM; Freund SM; Bycroft M; Fersht AR
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3142-7. PubMed ID: 19218448
[TBL] [Abstract][Full Text] [Related]
4. Structural diversity of p63 and p73 isoforms.
Osterburg C; Dötsch V
Cell Death Differ; 2022 May; 29(5):921-937. PubMed ID: 35314772
[TBL] [Abstract][Full Text] [Related]
5. Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation.
Jenkins LM; Yamaguchi H; Hayashi R; Cherry S; Tropea JE; Miller M; Wlodawer A; Appella E; Mazur SJ
Biochemistry; 2009 Feb; 48(6):1244-55. PubMed ID: 19166313
[TBL] [Abstract][Full Text] [Related]
6. Structural evolution of p53, p63, and p73: implication for heterotetramer formation.
Joerger AC; Rajagopalan S; Natan E; Veprintsev DB; Robinson CV; Fersht AR
Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17705-10. PubMed ID: 19815500
[TBL] [Abstract][Full Text] [Related]
7. Evolution of the p53-MDM2 pathway.
Åberg E; Saccoccia F; Grabherr M; Ore WYJ; Jemth P; Hultqvist G
BMC Evol Biol; 2017 Aug; 17(1):177. PubMed ID: 28774266
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of S100 proteins interacting with the p53 homologs p63 and p73.
van Dieck J; Brandt T; Teufel DP; Veprintsev DB; Joerger AC; Fersht AR
Oncogene; 2010 Apr; 29(14):2024-35. PubMed ID: 20140014
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the p300 Taz2-p53 TAD2 complex and comparison with the p300 Taz2-p53 TAD1 complex.
Miller Jenkins LM; Feng H; Durell SR; Tagad HD; Mazur SJ; Tropea JE; Bai Y; Appella E
Biochemistry; 2015 Mar; 54(11):2001-10. PubMed ID: 25753752
[TBL] [Abstract][Full Text] [Related]
10. Impact of cadmium, cobalt and nickel on sequence-specific DNA binding of p63 and p73 in vitro and in cells.
Adámik M; Bažantová P; Navrátilová L; Polášková A; Pečinka P; Holaňová L; Tichý V; Brázdová M
Biochem Biophys Res Commun; 2015 Jan; 456(1):29-34. PubMed ID: 25446071
[TBL] [Abstract][Full Text] [Related]
11. Conformational stability and activity of p73 require a second helix in the tetramerization domain.
Coutandin D; Löhr F; Niesen FH; Ikeya T; Weber TA; Schäfer B; Zielonka EM; Bullock AN; Yang A; Güntert P; Knapp S; McKeon F; Ou HD; Dötsch V
Cell Death Differ; 2009 Dec; 16(12):1582-9. PubMed ID: 19763140
[TBL] [Abstract][Full Text] [Related]
12. The p73 DNA binding domain displays enhanced stability relative to its homologue, the tumor suppressor p53, and exhibits cooperative DNA binding.
Patel S; Bui TT; Drake AF; Fraternali F; Nikolova PV
Biochemistry; 2008 Mar; 47(10):3235-44. PubMed ID: 18260640
[TBL] [Abstract][Full Text] [Related]
13. Differences in the transactivation domains of p53 family members: a computational study.
Mavinahalli JN; Madhumalar A; Beuerman RW; Lane DP; Verma C
BMC Genomics; 2010 Feb; 11 Suppl 1(Suppl 1):S5. PubMed ID: 20158876
[TBL] [Abstract][Full Text] [Related]
14. C-terminal α Domain of p63 Binds to p300 to Coactivate β-Catenin.
Katoh I; Maehata Y; Moriishi K; Hata RI; Kurata SI
Neoplasia; 2019 May; 21(5):494-503. PubMed ID: 30986748
[TBL] [Abstract][Full Text] [Related]
15. The dominant-negative interplay between p53, p63 and p73: A family affair.
Billant O; Léon A; Le Guellec S; Friocourt G; Blondel M; Voisset C
Oncotarget; 2016 Oct; 7(43):69549-69564. PubMed ID: 27589690
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the oligomeric state and transactivation potential of TAp73α.
Luh LM; Kehrloesser S; Deutsch GB; Gebel J; Coutandin D; Schäfer B; Agostini M; Melino G; Dötsch V
Cell Death Differ; 2013 Aug; 20(8):1008-16. PubMed ID: 23538419
[TBL] [Abstract][Full Text] [Related]
17. Structure of p73 DNA-binding domain tetramer modulates p73 transactivation.
Ethayathulla AS; Tse PW; Monti P; Nguyen S; Inga A; Fronza G; Viadiu H
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6066-71. PubMed ID: 22474346
[TBL] [Abstract][Full Text] [Related]
18. Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence code.
Ciribilli Y; Monti P; Bisio A; Nguyen HT; Ethayathulla AS; Ramos A; Foggetti G; Menichini P; Menendez D; Resnick MA; Viadiu H; Fronza G; Inga A
Nucleic Acids Res; 2013 Oct; 41(18):8637-53. PubMed ID: 23892287
[TBL] [Abstract][Full Text] [Related]
19. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.
Gaiddon C; Lokshin M; Ahn J; Zhang T; Prives C
Mol Cell Biol; 2001 Mar; 21(5):1874-87. PubMed ID: 11238924
[TBL] [Abstract][Full Text] [Related]
20. Identification of DeltaN isoform and polyadenylation site choice variants in molluscan p63/p73-like homologues.
Muttray AF; Cox RL; Reinisch CL; Baldwin SA
Mar Biotechnol (NY); 2007; 9(2):217-30. PubMed ID: 17242983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
